ProKidney announced its Q3 2026 financial results, highlighting progress in its Phase 3 PROACT 1 trial for chronic kidney disease treatment. The company expects topline results for the surrogate endpoint (eGFR slope) in Q2 2027 and aims to complete full enrollment by Q1 2027 with over 500 patients. ProKidney presented new clinical data supporting its lead therapy rilparencel at ASN Kidney Week 2026, reinforcing its potential to stabilize kidney function in advanced CKD and type 2 diabetes. The company ended Q3 with $142 million in cash, supporting operations into mid-2027.
ProKidney's Q3 2026 financial update comes as the health sector on Pluang shows broad declines, with 124 of 150 US health stocks falling as of Nov 13, 2026 04:11 WIB. For readers following health stocks, here is Pluang's market snapshot: Sana Biotechnology Inc (SANA) traded at USD 2.02 with a 1-day change of -11.79% and a typical hold time of 26 days, while Citius Pharmaceuticals Inc (CTXR) rose 11.19% to USD 0.53 despite 84% of Pluang orders being sell orders. Summit Therapeutics Inc (SMMT) fell 9.25% to USD 15.10 with a typical hold time of 19 days and a 43% sell order ratio.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
